| 0.4268 -0.028 (-6.12%) | 06-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.82  |
1-year : | 1.02 |
| Resists | First : | 0.7 |
Second : | 0.87 |
| Pivot price | 0.52 |
|||
| Supports | First : | 0.41 |
Second : | 0.34 |
| MAs | MA(5) : | 0.47 |
MA(20) : | 0.56 |
| MA(100) : | 2.14 |
MA(250) : | 2.96 |
|
| MACD | MACD : | -0.2  |
Signal : | -0.3 |
| %K %D | K(14,3) : | 5.6 |
D(3) : | 7 |
| RSI | RSI(14): 19.6 |
|||
| 52-week | High : | 5.32 | Low : | 0.41 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ MDXH ] has closed above bottom band by 1.1%. Bollinger Bands are 78.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 15 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.48 - 0.49 | 0.49 - 0.49 |
| Low: | 0.41 - 0.42 | 0.42 - 0.42 |
| Close: | 0.44 - 0.45 | 0.45 - 0.45 |
MDxHealth SA is a commercial-stage precision diagnostics firm delivering specialized urologic solutions across the globe. Its international footprint includes the United States, various European nations such as the Netherlands, Belgium, Spain, Poland, Italy, and the wider European Union. The company's innovative genomic testing portfolio for prostate cancer comprises SelectMDx, a non-invasive urine test, and ConfirmMDx, an epigenetic diagnostic tool. These advanced offerings enable medical professionals to precisely identify clinically significant prostate cancer, thereby minimizing reliance on invasive procedures and their associated risks. Established in 2003, with its headquarters in Herstal, Belgium, the entity was formerly known as OncoMethylome Sciences SA until its renaming to MDxHealth SA in October 2010.
Fri, 26 Jun 2026
MDxHealth S.A. Actuals & Estimates (NASDAQ:MDXH) - TradingView
Thu, 25 Jun 2026
MDXH Forecast — Price Target — Prediction for 2027 - TradingView
Tue, 23 Jun 2026
MDXH PE Ratio & Valuation, Is MDXH Overvalued - Intellectia AI
Wed, 17 Jun 2026
MDxHealth SA (MDXH) Institutional Confidence - TradingKey
Wed, 03 Jun 2026
MDxHealth (MDXH) awards new share options to finance VP - Stock Titan
Thu, 14 May 2026
Mdxhealth Exits Resolve Business, Refocuses on Prostate Cancer as Q1 2026 Revenue Rises 13% - The Globe and Mail
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 0 (M) |
| Shares Float | 51 (M) |
| Held by Insiders | 3.624e+007 (%) |
| Held by Institutions | 11.1 (%) |
| Shares Short | 52 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -0.65 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.39 |
| Profit Margin | -29.9 % |
| Operating Margin | -26.7 % |
| Return on Assets (ttm) | -6.4 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 12.6 % |
| Gross Profit (p.s.) | 71983.9 |
| Sales Per Share | 112921 |
| EBITDA (p.s.) | -10908.5 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -1 (M) |
| Levered Free Cash Flow | -15 (M) |
| PE Ratio | -0.69 |
| PEG Ratio | 0 |
| Price to Book value | -1.15 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.01 |
| Dividend | 0 |
| Forward Dividend | 457830 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|